Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by StockReddyon Jul 01, 2020 9:52pm
229 Views
Post# 31213991

Plasma therapy is especially important and last option

Plasma therapy is especially important and last optionPlasma therapy is especially important and last option to treat and save hundreds of thousands of people’s lives in this health emergency. The good thing is LMNL have expertise in this category and high number of recovered patients from COVID-19 to donor plasma.

 I guess the SP will keep raising based on the performance of the company.

https://stockhouse.com/news/press-releases/2020/06/30/liminal-biosciences-commences-collection-of-convalescent-plasma-from-covid-19

"We are proud to be collecting COVID-19 convalescent plasma to be potentially used in the manufacture of hyperimmune immunoglobulins by third parties and be a part of this historic effort which aims to accelerate a reliable, scalable and sustainable option for patients suffering from the impact of COVID-19.", stated Kenneth Galbraith, Chief Executive Officer of Liminal BioSciences. "We expect that developing a hyperimmune will require third parties to collect plasma donations from many individuals who have fully recovered from COVID-19 and we encourage anyone who has recovered from COVID-19 without symptoms for 14 days to come forward and donate plasma to this worthy cause."

GOOD LUCK TO ALL!
<< Previous
Bullboard Posts
Next >>